NeoGenomics (NASDAQ:NEO) Downgraded by Zacks Investment Research to Sell

0
53

NeoGenomics stock has undergone multiple analysts rating changes in the recent past.  NeoGenomics Downgraded by Zacks Investment Research on 10/27/2021. In a note to investors, the firm issued a new rating of Sell. The analysts previously had rating of Hold.

Shares of NeoGenomics traded down -$0.95 on Tuesday, reaching $44.92. 88173 shares of the stock traded hands, compared to its average volume of 1184622. Shares of NeoGenomics were trading at $44.92 on Tuesday. The firm’s 50 day moving average is $46.50 and its 200 day moving average is $47.00.NeoGenomics has a 12 month low of $44.63 and a 12 month high of $61.57. While on yearly highs and lows, NeoGenomics’s today has traded high as $46.12 and has touched $44.63 on the downward trend. See More Analyst Rating at: RATING

NeoGenomics Earnings and What to expect: 

NeoGenomics last issued its earnings data on August 6th, 2021. The medical research company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.04. The business had revenue of $121.72 million for the quarter, compared to the consensus estimate of $120.50 million. NeoGenomics has generated $0.07 earnings per share over the last year ($0.57 diluted earnings per share) and currently has a price-to-earnings ratio of 80.5. Earnings for NeoGenomics are expected to grow in the coming year, from ($0.34) to ($0.30) per share. NeoGenomics has confirmed that its next quarterly earnings report will be published on Thursday, November 4th, 2021. NeoGenomics will be holding an earnings conference call on Thursday, November 4th at 8:30 AM Eastern. Interested parties can or dial in at 919-882-2331 with passcode “43244”.

Earnings for NeoGenomics are expected to grow in the coming year, from ($0.34) to ($0.30) per share. The P/E ratio of NeoGenomics is 80.48, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 15.30. The P/E ratio of NeoGenomics is 80.48, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 33.38. NeoGenomics has a P/B Ratio of 7.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

NeoGenomics (NASDAQ:NEO) Moving Average Technical Analysis

5 day Moving Average is $45.08 And 5 day price change is $0.49 (1.08%)  with average volume for 5 day average is 529,000. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $44.35 and 20 day price change is -$0.39 (-0.84%) and average 20 day moving volume is 1,113,005. 50 day moving average is $46.50  and 50 day price change is $3.66 ( 8.67%)  and with average volume for 50 days is : 981,350. 200 day moving average is $47.00  and 200 day price change is -$7.47 (-14.00%)  and with average volume for 200 days is : 829,255.

Other owners latest trading in NeoGenomics :

  • On 10/26/2021 shares held by TCW Group Inc. were 266,312 which equates to market value of $12.85M and appx 0.00% owners of NeoGenomics
  • On 10/25/2021 shares held by Perkins Capital Management Inc. were 157,750 which equates to market value of $7.61M and appx 4.70% owners of NeoGenomics
  • On 10/25/2021 shares held by New York State Teachers Retirement System were 143,385 which equates to market value of $6.92M and appx 0.00% owners of NeoGenomics
  • In total Institutional ownership equates to Institutional Ownership Percentage: 90.05% for NeoGenomics

See More Analyst Rating at: RATING